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Abstract
Duchenne Muscular Dystrophy is a rare and fatal neuromuscular disease in which the absence of dystrophin from the
muscle membrane induces a secondary loss of neuronal nitric oxide synthase and the muscles capacity for
endogenous nitric oxide synthesis. Since nitric oxide is a potent regulator of skeletal muscle metabolism, mass, function
and regeneration, the loss of nitric oxide bioavailability is likely a key contributor to the chronic pathological wasting
evident in Duchenne Muscular Dystrophy. As such, various therapeutic interventions to re-establish either the neuronal
nitric oxide synthase protein deficit or the consequential loss of nitric oxide synthesis and bioavailability have been
investigated in both animal models of Duchenne Muscular Dystrophy and in human clinical trials. Notably, the efficacy
of these interventions are varied and not always translatable from animal model to human patients, highlighting a
complex interplay of factors which determine the downstream modulatory effects of nitric oxide. We review these
studies herein.
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Background
Duchenne Muscular Dystrophy (DMD) is a progressive
and fatal X-linked [1] neuromuscular disorder afflicting
1 in 3500–5000 live male births [2]. DMD arises from
the loss of dystrophin [3], a 427 kDa cytoskeletal protein
[4] that links the contractile apparatus to the sarco-
lemma via the dystrophin-associated protein complex
(DPC). Dystrophin is believed to provide stability and in-
tegrity to the muscle membrane during contraction and
in its absence, skeletal muscle is prone to damage. The
alterations to the membrane induced by dystrophin-
deficiency leads to an excessive influx of calcium (Ca2+)
from the extracellular environment, which is poorly
buffered, and activates Ca2+-dependent proteases to
induce a cascade of degeneration and damage. As the dis-
ease progresses, and damage and degeneration accrues,
the regenerative capacity of the muscle diminishes and be-
comes unable to match the demand for repair [5]. Muscle
is subsequently replaced with fibrous and/or fatty con-
nective tissue. Clinically, the increasing presence of non-
functional muscle leads to muscle weakness and loss of
function, with DMD sufferers wheelchair bound by early
adolescence and eventually succumbing to cardiorespira-
tory failure by the third decade of life [6].
It is most commonly accepted that the excessive influx
of Ca2+ into dystrophin-deficient myofibres is the cata-
lyst for dystrophinopathy. However, emerging evidence
suggests that metabolic and mitochondrial dysfunction
may play a significant role in disease progression [7–9].
Whether this dysfunction is a secondary consequence to
dystrophin-deficiency or independent is unknown, how-
ever a physical link between dystrophin and metabolism
exists in neuronal nitric oxide synthase (nNOS). nNOS is
an enzyme usually localised to the sarcolemma attached
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to the DPC, however in the absence of dystrophin, there is
a secondary reduction of nNOS [10, 11]. The loss of
nNOS from the sarcolemma reduces overall nNOS con-
tent in dystrophic muscle [12–15] resulting in decreased
nNOS activity [12–15] and NO production [16–18]. The
loss of nNOS protein and subsequently NO production
capacity and bioavailability, is detrimental to dystrophic
muscle for two reasons. Firstly, NO is an important signal-
ling molecule involved in many biological processes in-
cluding metabolism, blood flow and regulation of muscle
function and mass [19]. Secondly, the nNOS protein itself
interacts with phosphofructokinase (PFK), a regulatory en-
zyme of glycolysis, and is capable of increasing its activity
by 60-fold [20] thereby increasing glycolytic rate and cap-
acity. The loss of association between nNOS and PFK in
dystrophin-deficient muscle may help to explain the fatig-
ability of dystrophic muscle [21, 22] and may partially or
fully account for the various glycolytic impairments ob-
served [20, 23, 24]. In addition to the vast deficits in mito-
chondrial function (for detailed reviewed see [9]), these
metabolic impairments reduce energy production capacity
[7] and resting energy content [25, 26] which severely
limits the muscles capacity to buffer damage and facilitate
repair. As it appears that NO plays an important role
in metabolism and the maintenance of skeletal muscle
mass, restoring NO bioavailability in dystrophin-deficient
muscle may be beneficial (summarised in Table 1). Here,
we review the various approaches to restore NO bioavail-
ability in dystrophic muscle including nNOS overexpres-
sion, ˪-arginine administration, phosphodiesterase (PDE)
inhibition and nitrate supplementation, with a focus on
the effects on the architecture, function and metabolism
of dystrophin-deficient skeletal muscle.
Increasing nNOS substrate availability
NO is an important signalling molecule that elicits a myr-
iad of physiological effects through the production of cyclic
guanosine monophosphate (cGMP) and/or S-nitrosylation
of thiol residues of cysteine groups. cGMP is a second
messenger produced by the binding of NO to the enzym-
atic receptor soluble guanylyl cyclase (sGC) [27]. The in-
crease in cytoplasmic cGMP activates downstream cGMP
specific protein kinases, cation channels and PDEs which
then exert various biological effects [27]. NO also medi-
ates its effects through S-nitrosylation, a post-translational
modification of proteins that modulates enzyme activity,
protein stability and localisation [28]. Since the secondary
dissociation of nNOS from the sarcolemma in dystrophic
skeletal muscle reduces NO bioavailability, which would
impair a multitude of physiological processes that may
contribute to disease progression, various techniques to
increase NO production have been investigated.
Considering that nNOS delocalisation from the sarco-
lemma does not completely obliterate the nNOS protein
in dystrophic skeletal muscle [11], substrate availability,
in the form of ˪-arginine, may be a limiting factor to
nNOS-dependent NO production (Fig. 1). ˪-arginine
(50–100 mg/kg) administration in the mdx mouse dem-
onstrably improves sarcolemmal integrity as indicated by
increased utrophin – a dystrophin analogue – [18, 29–33]
and DPC protein expression [18, 30–33], reduced Evans
Blue Dye (EBD) uptake – a marker of skeletal muscle
membrane damage – [18, 32–34] and decreased serum
creatine kinase levels – a clinical marker of muscle
damage and disease progression [30, 32, 33]. In a
pilot trial involving 5 DMD patients, the combination
of ˪-arginine (7.5 g/day) and the pharmacological Adeno-
sine Monophosphate-activated Protein Kinase (AMPK)-
activator, metformin (500 mg/day), decreased resting
energy expenditure, shifted energy metabolism substrate
preference to fatty acids, reduced oxidative stress and im-
proved motor function [35]. NO is a known activator of
AMPK, highlighting that promoting both the production
of NO (i.e., with L-arginine) and the downstream meta-
bolic responses that are normally modulated by NO (i.e.,
with metformin) can functionally improve the metabolism
and function of dystrophic skeletal muscle. In a subse-
quent single-centre, randomised, placebo controlled-trial,
aimed at recruiting 40–50 DMD patients, the same group
is currently investigating the efficacy of combined ʟ-citrul-
line and metformin (NCT01995032; [36]) – ʟ-citrulline
was chosen for this trial it is an ʟ-arginine precursor that
can demonstrably restore muscular ʟ-arginine levels and
reduce muscle wasting in ʟ-arginine-deficient conditions,
while having a self-mediated effect on protein metabolism
via inducible (i)NOS which bypasses the obvious nNOS
deficiency [37]. ʟ-arginine therapy has also proven benefi-
cial to skeletal muscle in the mdx mouse (a genetically
homologous murine model of DMD). Histologically,
˪-arginine therapy improves many of the characteristic
myopathological hallmarks in mdx mice including reduc-
tions in fatty and fibrotic tissue and collagen deposition
[30–32, 38], inflammatory cell infiltration [31] and necro-
sis [18, 30, 32]. Functional improvements in grip strength
[32, 33], lesser decrement in strength with age [38], and
improved respiratory function [30, 32] were also observed.
In addition to these functional improvements, ˪-arginine
demonstrably reduces dystrophic muscle fatigability [33]
and improves contractile function [30, 32] resulting in an
increased capacity to exercise [34]. Whilst ˪-arginine ad-
ministration appears to be beneficial both in the mdx
mouse and DMD patients, the significantly reduced nNOS
content evident in DMD patients suggests that there is a
limited therapeutic application for ˪-arginine unless con-
comitant increases in nNOS expression could be achieved,
or alternative isoforms of NOS could be exploited (i.e.
through iNOS as per ʟ-citrulline therapy). This is espe-
cially true since ˪-arginine administration alone, especially
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in high doses, can have adverse side effects [39]. Indeed, a
recent paper describing metabolic biomarkers of DMD
demonstrates significantly elevated serum arginine con-
centrations in DMD patients as the disease progresses
[40], highlighting the possibility of an ineffective uptake ei-
ther alone or in combination with an ineffective metabol-
ism due to reduced nNOS protein at the skeletal muscle
level. While reduced ʟ-arginine transporter protein ex-
pression has been demonstrated in cardiac muscle from
two murine models of DMD (mdx and mdx/utrophin
double knockdown mice) [41], there is no data describing
this deficit in skeletal muscle either in mice or in human
DMD patients. Such a deficit would logically explain a re-
duced capacity for ʟ-arginine uptake resulting in plasma
accumulation, and may be a consequence of a reduced
capacity for metabolism by nNOS.
Restoring nNOS protein expression
Given that the limiting factor to nNOS substrate supple-
mentation therapy would be sufficient nNOS to catalyse
the NO-generating reaction, restoring nNOS protein,
particularly to the sarcolemma, presents as a strong
therapeutic candidate. Indeed, restoring nNOS levels in
dystrophic skeletal muscle has proven to be beneficial
(Fig. 1). Offspring of transgenic nNOS overexpressors
bred with the mdx mouse show a significant mitigation
of membrane damage as reflected by a reduction in
inflammation, macrophage and neutrophil infiltration,
centronucleation of fibres and membrane lesions [42, 43].
Introduction of this nNOS transgene also extends protect-
ive effects to the dystrophic heart by reducing fibrosis and
macrophage infiltration in conjunction with improving
impulse conduction [44]; and to the neuromuscular junc-
tion through improvements in neuromuscular junction
size and architecture in the presence of α-syntrophin [45].
Remarkably, nNOS restoration in dystrophin/utrophin
knockout mice (which phenotypically resemble DMD)
increases survival rate while reducing macrophage infiltra-
tion and the fibrotic and connective tissue content of
dystrophin deficient skeletal muscle [46]. Therefore,
Table 1 Summary of methods utilised to increase NO production and the effects observed in dystrophic skeletal and cardiac muscle
from DMD animal models and patients
Method/Mechanism Dosage Range Model Effects Other Reference
nNOS restoration
Breeding with
transgenic nNOS
overexpressors
Transfection with
nNOS
N/A mdx mouse
Dystrophin/utrophin
knockout mouse
mdx mouse
Skeletal muscle: reduces inflammation,
macrophage and neutrophil infiltration,
damage
Cardiac muscle: reduces fibrosis,
macrophage infiltration, improves
impulse conduction
Skeletal muscle: increases DPC expression,
NO production, reduces damage and
fatigue, prevents force production loss
[39–45, 47–49]
˪-arginine
supplementation
200–1000 mg/kg/day DMD patients
mdx mouse
Skeletal muscle: increases DPC expression,
reduces damage, fibrotic and fatty tissue
infiltration, inflammatory cell infiltration,
oxidative stress, improves grip strength,
contractile function and reduces fatigability
Administered in
combination with
metformin and
prednisone
[18, 29–36]
PDE inhibition
Sildenafil
Tadalafil
0.7–80 mg/kg/day
30–300 mg/kg/day
DMD patients
mdx mouse
DMD patients
mdx mouse
Skeletal muscle: reduces collagen and
inflammatory cell infiltration, improves
sarcolemmal integrity
Cardiac muscle: reduces membrane
permeability, induces cardiac remodelling,
improves heart function
Skeletal muscle: improves functional ischemia,
reduces contraction-induced damage, fibrotic
infiltration, histological variability, improves
exercise performance, increases expression
of ETC. genes
[52, 55, 57–61]
NO donation 21–80 mg/kg/day mdx mouse Skeletal muscle: increases vascularisation,
blood flow, exercise performance and
strength, decreases free Ca2+ concentration,
damage, inflammation, fibrotic and
collagenous infiltration
Cardiac muscle: decreases damage,
inflammation, fibrotic and collagenous
infiltration, improves cardiac function
and architecture
Administered in
combination with
NSAIDs
[62–69]
Expansion of
nitrate-nitrite-
NO pool
85 mg/L mdx mouse Skeletal muscle: does not improve
mitochondrial deficits, increases damage
and peroxynitrite production
Only one study
to date
[107]
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increased expression of nNOS has a protective effect on
maintaining muscle architecture and preventing mem-
brane lysis through the normalisation of NO production
[47]. Moreover, transfection with a modified muscle spe-
cific nNOSμ isoform – which localises to the membrane
without the presence of dystrophin – resulted in increased
expression of utrophin and other DPC proteins (including
α-syntrophin and β-dystroglycan) which induced localised
NO production at the sarcolemma and protection against
contraction-induced damage and fatigue [48]. In contrast,
an unmodified nNOSμ afforded less protection than the
modified muscle-specific nNOSμ isoform in the same
study [48]. This appears to be reflective of the binding of
the modified NOS to the membrane via palmitoylation
which induced utrophin expression. While the mechanism
as to why membrane-localised nNOS induces utrophin
expression is unclear. This utrophin upregulation seems
to protect dystrophic mdx muscle from progressive
damage, particularly as mdx mice age [49], thus at-
tenuating the dystrophic phenotype despite the absence of
dystrophin expression. Insertion of a mini-dystrophin
gene via a dual adeno-associated viral vector which in-
creases mini-dystrophin expression and restores nNOS at
the sarcolemma [50], has also been shown to improve
contraction-induced ischemia and mitigate the loss of
force production and muscle damage [51, 52]. Collectively,
these data highlight that increased expression of the
nNOS protein, irrespective of localisation within the cell,
can improve various characteristics of the dystrophic con-
dition. However, there may be limited long-term thera-
peutic potential for nNOS overexpression as a delocalised
nNOS (from the sarcolemmal DPC) becomes a substrate
of calpains [53]. Calpains are enzymes that stimulate pro-
tein damage and are particularly active in DMD pathology
[54]. Thus increased calpain activity may significantly
reduce unbound nNOS expression and induce further
non-specific protein damage. Since nNOS deficiency
has also been documented to increase ryanodine
receptor-mediated Ca2+ leak [55], which would per-
petuate Ca2+-dependent calpain activity, these data in-
dicate that there is necessity in dual upregulation of
nNOS and dystrophin to minimise unbound nNOS as
Fig. 1 Schematic of methods utilised to increase NO bioavailability in dystrophic skeletal muscle and the downstream effects. Increasing NO
bioavailability through (1) restoration of nNOS, (2) -arginine supplementation, (3) NO donation and (4) inhibition of the enzyme phosphodiesterase
(PDE) has led to increases in mitochondrial function, exercise capacity and stabilisation of the membrane in dystrophin-deficient skeletal muscle. A
potential consequence of increased NO bioavailability, as observed through nitrate supplementation (5), is peroxynitrite (ONOO−) formation which can
lead to further muscle damage and is undesirable in dystrophic skeletal muscle
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a target for calpains which would promote the disease
phenotype.
Inhibition of phosphodiesterase activity
Given that enhancing NO production capacity is benefi-
cial in dystrophic muscle yet there are complexities asso-
ciated with re-insertion/establishment of dystrophin and
nNOS expression, other mechanisms to increase NO
bioavailability have been investigated. One such avenue
is the inhibition of the PDE family which breakdown
phosphodiester bonds in second messenger molecules
[56]. Specific PDEs hydrolyse cGMP thereby degrading it
and decreasing cGMP second messenger capacity [56].
Since NO activates cGMP cycling, and it’s production and
bioavailability is reduced in dystrophic muscle, pharmaco-
logically prolonging/amplifying the cGMP signal would
have likely benefits in NO-deficient cells (Fig. 1).
Inhibition of PDE5A has been commonly investigated
in the mdx mouse as PDE5A is present not only in vas-
cular smooth muscle [57], but also skeletal muscle [58]
and to a lesser extent cardiac muscle [59], thereby
allowing for a systemic effect of a prolonged NO signal in
these tissues. Treatment with Tadalafil (1 mg/100 mL), a
pharmacological PDE5A inhibitor, has shown to be
beneficial in overcoming functional ischaemia follow-
ing contraction, which was partnered with reduced
contraction-induced sarcolemmal damage and muscle
fibre death [60]. Tadalafil treated mdx muscles (30 mg/kg/
day) also demonstrated histological improvements with a
decrease in EBD uptake, fibrotic infiltration, centronu-
cleated fibres and fibre size variability [60, 61] suggesting
less damage and prevention of muscle degeneration.
Additionally, exercise-induced damage was minimised in
Tadalafil treated mice as evidenced by reduced Ca2+ accu-
mulation [61]. Functionally, time to exhaustion from
treadmill running and extensor digitorum longus (EDL)
strength were concomitantly improved following Tadalafil
treatment [61] in addition to post-exercise increases in ac-
tivity and reductions in serum creatine kinase and muscle
oedema [62]. PGC-1α expression was also increased fol-
lowing Tadalafil treatment alongside an enhanced expres-
sion of various electron transport chain genes suggestive
of a fibre type shift to an oxidative phenotype [61]. Con-
sidering the vast mitochondrial and oxidative metabolism
deficiencies observed in dystrophic muscle [9], upregula-
tion of mitochondrial and oxidative genes would likely be
beneficial to dystrophic muscle. Only two studies to date
have documented the successful translation of Tadalafil
treatment into small populations of DMD [63] and Becker
Muscular Dystrophy (BMD) [64] patients. Although these
trials were small, and primarily assessed improvements in
functional muscle ischaemia as an endpoint measure,
these results demonstrate that the beneficial effects of
PDE5A inhibitors in pre-clinical studies are translatable in
patients with dystrophin-deficiency. In particular, both of
these studies utilised an acute treatment protocol (up to
2 days) with endpoint measures assessed an hour following
treatment indicating an effect of PDE5A inhibition in these
populations. A recent study by Hammers et al. [65] has
also demonstrated a cardioprotective role for Tadalafil
whereby a daily dosage of 1 mg/kg for 16 months re-
duced dystrophy-related histopathological features, calpain-
mediated proteolysis and preserved cardiac function (as
assessed by echocardiography and MRI). A notable limita-
tion to this study was the low number of animals utilised
(n = 2 DMD and control).
Similar results have been observed with the alternative
PDE5A inhibitor, Sildenafil. In mdx mice, Sildenafil
demonstrably increases specific force, reduces collagen I,
fibronectin and TNFα infiltration, and improves sarco-
lemmal integrity of the diaphragm [66]. However, these
improvements did not result in changes to mitochon-
drial function nor improvements in ATP production as
originally hypothesised [67]. Since DMD patients typic-
ally succumb to respiratory failure, these data import-
antly highlight the potential for Sildenafil to prolong the
lifespan of DMD patients should diaphragmatic im-
provements be translatable in the clinical setting. Fol-
lowing phenotypic drug screening in dystrophic
zebrafish, a PDE inhibitor (aminophylline), which has
similar properties to Sildenafil, was shown to have the
greatest capacity to restore normal skeletal muscle
structure [68]. The group later demonstrated beneficial
effects of Sildenafil in the mdx5cv mouse model via en-
hanced signalling of haemoxygenase and downstream
cGMP [69]. Sildenafil also appears to induce protective
effects in the mdx heart by reducing membrane permeabil-
ity and altering the expression of proteins implicated in
beneficial cardiac remodelling [70]. Functionally, Sildenafil
normalises heart rate responses to increasing workload
[70] and reverses ventricular dysfunction [71]. Again, since
cardiac complications reduce lifespan in DMD patients,
these data appear to be promising should they be translat-
able in the clinical setting.
Collectively, the studies investigating PDE inhibition
suggest that amplification of the typically NO-dependent
cGMP signal benefits both skeletal and cardiac function
and mitigates various characteristics of the dystrophic
condition in the mdx mouse, and in an acute setting, is
beneficial in both DMD and BMD patients. Recently,
however, a Phase 3 clinical trial of Sildenafil in DMD
and BMD boys was prematurely stopped following the
absence of improvements in skeletal muscle function and
adverse changes to left ventricle volumes (NCT01168908;
[72]). In a parallel Sildenafil trial in only BMD patients,
the clinical trial was completed but no obvious bene-
fit to patients was observed (NCT01350154; [73]).
Most recently, a Phase 3 clinical trial in only DMD
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patients investigating the capacity of Tadalafil to slow
the decline of ambulation was prematurely terminated
due to lack of efficacy. These clinical data indicate
that Tadalafil and Sildenafil are not translatable drugs
from pre-clinical studies to patients with DMD when
the patients receive treatment for a chronic period of time
(i.e., 6 months) or are on standard of care (SoC) therapy.
While the inhibition of PDE5A is pre-clinically viable (i.e.,
in mouse, zebrafish and dog models), it must be kept in
mind that these preclinical studies were not performed in
conjunction with SoC therapies (i.e., prednisone or defla-
zacort). From a pharmacological standpoint, both Tadalafil
and Sildenafil are drugs marketed for a specific indication
(Tadalafil for erectile dysfunction and benign prostatic
hyperplasia, Sildenafil for erectile dysfunction and
pulmonary arterial hypertension) that happened to find
efficacy in other indications both pre-clinically and clinic-
ally. The hope of testing drugs like Tadalafil and Sildenafil
are that they are already FDA approved, albeit for other
indications, and have known safety margins. However, the
recent discovery that BMD patients, who express a trun-
cated version of dystrophin, are also deficient in PDE5A
[73] suggests limitations to this therapeutic avenue. This
deficiency highlights that as per nNOS, the expression of
PDE is intimately linked with dystrophin and/or DPC ex-
pression, and that the capacity to exploit them pharma-
cotherapeutically is therefore limited in DMD. As such,
no improvements in cardiac function, blood flow to the
skeletal muscle during exercise, or quality of life were ob-
served in BMD patients [73].
NO donors
Since ʟ-arginine and PDE activation are both dependent
upon the presence of key enzymes/proteins associated
with the sarcolemma, and more specifically, the DPC,
promoting NO production through the use of NO donors
may be of greater benefit to bypass this defective/inefficient
protein system. As there is limited nNOS present in
dystrophin-deficient skeletal muscle, this significantly im-
pairs the muscles capacity for NO production. Therefore,
even with PDE inhibition, the availability of NO would still
be significantly diminished. Thus, the use of NO donors is
an attractive therapeutic treatment option as they have the
capacity to markedly increase systemic NO availability
beyond the capacity to endogenously produce it within
dystrophic muscle (Fig. 1).
Indeed, 6 months delivery of a nitric ester derivative of
sedative alkyl alcohol (administered at 40 mg/kg 5 days/
week) has been shown to enhance the vascular density
of skeletal muscle, as well as exercise performance and
strength in mdx mice, with a marked decrease in the
free intracellular Ca2+ concentration of skeletal muscle
[74]. In addition, the NO-donating nitric ester increased
muscle fibre size while concomitantly reducing the
population of regenerating fibres, suggestive of de-
creased damage [74]. Similarly, 7 months of 30 mg/kg
naproxcinod, a non-steroidal anti-inflammatory drug
(NSAID) with NO-donating properties, in food, had a
beneficial effect on the running capacity of mdx mice
with both time to exhaustion and whole body strength
improved [75]. These functional benefits were partnered
with improved muscle architecture, and reductions in
inflammatory, fibrotic and collagen infiltrate observed in
both skeletal and cardiac muscle [75]. Longer term ad-
ministration of naproxcinod (at 21 mg/kg/day in food
for 9 months) induces similar improvements in the
strength and histological properties of cardiac muscle
leading to the functional normalisation of ejection frac-
tion time, and systolic blood pressure [76]. Considering
the anti-inflammatory effects of the aforementioned
NO-donors, combining a NO donor with NSAIDs could
enhance the beneficial effects of NO. Three months of a
HCT 1026-enriched diet (NO donor derived from flurbi-
profen; 45 mg/kg/day) significantly improved blood flow
and alleviated functional ischaemia in mdx mice [77]. A
longer term supplementation regimen of the same drug
(30 mg/kg/day in food for 12 months) was shown to re-
duce muscular damage, with concomitant decreases in
serum creatine kinase levels and improved mobility of
mdx mice [78]. Moreover, the addition of isosorbide
dinitrate (30 mg/kg/day) with ibuprofen (50 mg/kg/day)
has been shown to induce significant protection of the
dystrophic heart by normalising left ventricle mass and
wall thickness, maintaining cardiomyocyte number and
reducing cross sectional area. Reduced fibrotic tissue
content and inflammatory cell infiltration and a con-
comitant improvement in overall cardiac function was
also observed in the mdx mouse [79]. Isosorbide dini-
trate, alone (66 mg/kg) or in combination with prednis-
one (1 mg/kg) for 18 days, also demonstrably improves
sarcolemmal integrity, decreases the presence of calcified
fibres and stimulates regeneration in the mdx dia-
phragm, however without the addition of ibuprofen, it
promoted an increase in heart weight [80] which was not
observed previously [79]. An increase in cardiac mass,
without improvements in cardiac function, is considered
an adverse effect of treatment which would promote the
normal, progressive cardiac hypertrophy observed in
DMD patients. Ibuprofen seems to abate this adverse ef-
fect since a safety study in DMD patients using 12 months
of isosorbide dinitrate (40 mg/day) and ibuprofen
(400 mg/day) maintained cardiac function and reduced
systemic inflammatory markers [81]. Given there is the
capacity for non-specific, systemic NO-donors to ad-
versely affect cardiac tissue, the use of skeletal muscle tar-
geted NO donation would be beneficial. Indeed, oral
administration of MyoNovin (80 mg/kg) – a NO donor
that specifically donates NO to skeletal muscle – for
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18 days induces similar effects to isosorbide dinitrate in
mdx mice without the adversity of cardiac hypertrophy in-
duction [80]. As the majority of the investigated NO
donor therapies have additional indications (i.e., as anti-
inflammatories (ibuprofen) or muscle relaxants (MyoNo-
vin)), it is difficult to separate out the benefits specifically
provided by donated NO and it is possible that that these
alternative indications may be the more pertinent effec-
tors. Given that uncontrolled and excessive NO delivery
can induce pathological effects including inflammation,
mitochondrial dysfunction and myocardial damage [82],
these data suggest that manipulation of the NO-donation
delivery system may be pivotal to mitigating the unwanted
side effects of NO donor therapy. As delivery of NO to
the skeletal muscle is difficult to control with pharmaco-
logical NO donors, and needs to be highly regulated since
changes in NO concentration can be either beneficial,
deleterious or insignificant to the promotion of Ca2+
dysregulation [83], availability of a constant yet buffered
reserve of NO is important.
Nitrate supplementation
Recently, it has emerged that dietary supplementation
with nitrate increases endogenous NO production via a
nNOS-independent pathway (Fig. 1). Nitrate is an inor-
ganic anion that is abundant in green leafy vegetables in-
cluding beetroot, lettuce and spinach [84] and also in
carrot, beetroot and pomegranate juices [85]. The nitrate
anion is inert but once ingested, nitrate is reduced by
the commensal bacteria in the enterosalivary pathway
[86] into the bioactive nitrite, which then circulates in
the blood. Although bioactive, nitrite is further con-
verted to NO via several enzymatic pathways in the
blood and tissues, including xanthine oxidase, myoglobin
and haemoglobin [87], to exert a range of physiological
effects. Thus, this pathway is complementary to nNOS-
derived NO production. Additionally, there is benefit to
this nitrate-nitrite-NO pathway as it is reversible. NO
can be oxidised back to nitrate by myoglobin and
haemoglobin and therefore the capacity to cycle back to
nitrate allows for a constant reservoir of NO [88]. More-
over, since chronic increases in NO bioavailability can be
toxic and induce systemic pathology [82], having an in-
active reservoir of buffered NO would be beneficial.
Therefore, enhancing the nitrate-nitrite-NO pathway
represents a potential pathway that could be exploited to
significantly enhance NO availability in dystrophic
muscle in a controlled and buffered manner.
Recent studies suggest that nitrate supplementation en-
hances health and skeletal muscle performance. A 3 day
oral supplementation of sodium nitrate (0.1 mmol/kg/day)
in healthy males revealed that nitrate significantly im-
proved skeletal muscle mitochondrial bioenergetics by in-
creasing mitochondrial efficiency and decreasing proton
leak; and reduced whole body oxygen consumption fol-
lowing submaximal exercise [89]. Moreover, a 7 day sup-
plementation regimen in drinking water of healthy mice
(~3.75 μmol/day) significantly improved skeletal muscle
contractility, particularly of the EDL, by increasing expres-
sion of Ca2+ handling proteins [90]. Similar improvements
in contractile function have also been observed in humans
following acute supplementation with nitrate-rich beetroot
juice (0.6 g/300 ml), with the authors noting improved
excitation-contraction coupling (at low frequencies) and
increased explosive force production in quadriceps [91].
Acute beetroot supplementation also demonstrably re-
duces whole body oxygen consumption [92–95], promotes
fatigue resistance [96–99] and improves performance
times [97, 100, 101]. Similar data has been observed in rats
using dietary sodium nitrate supplementation in drinking
water (0.7 mM), which stimulated mitochondrial biogen-
esis (peroxisome proliferator-activated receptor β/δ and
PGC-1α expression) and enhanced bioenergetics in both
skeletal [102] and cardiac muscle [103] indicating that
acute exposure to nitrate supplementation has a modula-
tory effects on bioenergetics.
The benefits of nitrate supplementation also extend to
disease states. In chronic obstructive pulmonary disease
patients, acute beetroot juice supplementation improved
exercise capacity and decreased blood pressure [104, 105].
Similar findings – in addition to increased tissue oxy-
genation – were observed in peripheral artery disease
patients [106]. Considering that dystrophic muscle is
in a comparable metabolically-stressed state to exer-
cising muscle in that there is an increased metabolic
demand and sarcoplasmic [Ca2+], and that nitrate
supplementation can elicit positive physiological re-
sponses in diseased tissue, investigating such a ther-
apy for DMD is rational.
To date, we are the only group to have investigated ni-
trate supplementation in the mdx mouse and its down-
stream effects on muscle metabolism and architecture
[107]. Previously, it was demonstrated that 8 weeks of
85 mg/L sodium nitrate in drinking water ameliorated
metabolic syndrome in endothelial NOS-deficient mice
by increased circulating plasma NO levels [108], suggest-
ing that similar improvements could be observed in the
mdx mouse through the restoration of NO availability.
As metabolic dysfunction and insufficiency is a domin-
ant feature of dystrophin-deficient muscle, we investi-
gated two metabolic pathways that can be mediated by
NO — glucose uptake and mitochondrial function. We
demonstrated normal basal- and contraction-induced
glucose uptake in mdx muscles, which is consistent with
previous reports of normal insulin-dependent glucose up-
take (which is NO-independent) in dystrophin-deficient
muscle [109]. However, nitrate supplementation was un-
able to improve the depressed mitochondrial respiration
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observed in the white and red portions of the gastrocne-
mius in this study and as reported by us [7] and others
previously ([8, 110, 111]. In fact, nitrate reduced the
maximal respiration in the red gastrocnemius and failed
to increase markers of mitochondrial biogenesis such as
mitochondrial electron transport chain complex proteins.
Our data is consistent with the recent observation that
nuclear-specific NO production via localised nNOS is
important to modulate nuclear-regulated mitochondrial
biogenesis in skeletal muscle [112]. Thus, non-specific and
unregulated NO generation by non-nNOS sources ap-
pears to be futile in the absence of nNOS expression and
its regulatory function.
One benefit of nitrate supplementation in mdx mice
that we did observe was reduced hydrogen peroxide
generation, indicating reduced oxidative stress at the
mitochondrial level [107]. Outright, the reduction in
hydrogen peroxide appeared to be a positive effect; how-
ever, it occurred concomitant with a significant increase
in reactive nitrogen species generation as determined by
the immunolabelling of nitrotyrosine, an indirect marker
of peroxynitrite. Peroxynitrite formation corresponded
with increased damage of the tibialis anterior muscle
as assessed by haematoxylin and eosin staining [113].
Our finding is in stark contrast to those who have
previously demonstrated decreased muscle damage
through NO donor therapy [78, 114], highlighting
that the anti-inflammatory compounds often adminis-
tered in combination with the NO donor in these
studies, may be efficaciously offsetting the inflamma-
tory response that can be induced by both NO and
NO-induced peroxynitrite-mediated damage.
One clinical trial has also investigated sodium nitrate
therapy in BMD patients. In this study, an acute single
oral nitrate dose (140 mL beetroot juice concentrate
containing 8.4 mmol inorganic nitrate) was shown to
improve functional sympatholysis and post-exercise
hyperaemia in ambulatory BMD patients [115]. While
we did not measure these parameters in our study, it is
most likely that the beneficial effects elicited by nitrate
in BMD patients is reflective of the presence of both
dystrophin and nNOS in their skeletal muscle, albeit
these proteins are often severely, but not exclusively, re-
duced in BMD patients compared to healthy individuals
[115]. It appears that there is a defined level of nNOS
protein, or localisation of nNOS, that must be expressed
in skeletal muscle to ensure that the normal and benefi-
cial modulatory effects of bioavailable NO are exerted
within the muscle. Indeed, this is apparent not only in
our study but also in that of Nelson et al. [115] who re-
ported several BMD patients that were non-responsive
to nitrate therapy. This effect may be due to a more ad-
vanced disease/clinical state in these particular patients
in which nNOS protein levels become reduced below
threshold levels due to escalating dystropathology (i.e.,
protease activity).
Conclusions
NO plays an important role in a variety of biological
processes and in dystrophin-deficient muscle where NO
production is limited due to the secondary reduction of
nNOS, it is likely a significant contributor to disease pro-
gression. While improvements in muscle function, archi-
tecture and metabolism have been demonstrated using
various methods to increase NO bioavailability including
restoration of the nNOS protein, ˪-arginine supplementa-
tion and PDE inhibition, there are also limitations and/or
side effects that need to be addressed. This is particularly
true since the beneficial effects observed in pre-clinical
animal models of DMD have largely failed to translate
to clinical improvements in DMD patients. In the one
ʟ-arginine supplementation study that has successfully
translated in a clinical human DMD pilot trial, these pa-
tients were notably steroid naïve, and thus not receiving
SoC treatment. These data highlight important drug/func-
tional interactions that clearly require further elucidation.
There are also variations in the outcomes at the muscle
fibre level with different models of NO induction. For ex-
ample, beneficial effects have been observed with NO do-
nors, typically in addition with anti-inflammatories or
which have additional alternate functions at the muscle
level (i.e., as muscle relaxants as per MyoNovin), but not
with nitrate supplementation. Moreover, it appears that
chronic manipulation of the nitrate-nitrite-NO pathway
may not be a viable therapeutic option for DMD given its
tendency to promote damage and further dystropathology.
While we are currently the only group to have investigated
nitrate supplementation as a therapy for DMD, our find-
ings suggest that long-term/chronic nitrate supplementa-
tion is detrimental to dystrophin-deficient muscle and
may require a concomitant increase in nNOS protein ex-
pression to impart the same benefits it does in healthy
muscle. This idea is supported by the beneficial effects
seen in BMD patients following acute sodium nitrate sup-
plementation, who express low, yet detectable, levels of
both dystrophin and nNOS. However, further investiga-
tion is required to fully elucidate this intimate relationship.
Targeting NO delivery to skeletal muscle with the con-
comitant induction of nNOS protein expression, appears
to be a logical future direction in the utilisation of NO do-
nation as a therapy for DMD. The translational capacity of
this research however must address nNOS therapies in
conjunction with SoC (i.e., prednisone, deflazacort), as this
research is currently lacking in pre-clinical animal models.
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